Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study.

被引：6
|
作者：
Tam, Constantine Si Lun
Roberts, Andrew Warwick
Anderson, Mary Ann
Dawson, Sarah-Jane
Hicks, Rodney J.
Burbury, Kate
Turner, Gillian
Di Iulio, Juliana
Bressel, Mathias
Westerman, David A.
Agarwal, Rishu
Pott, Christiane
Dreyling, Martin H.
Dawson, Mark A.
Seymour, John Francis
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.7520
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7520
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)
    Lee, Hun Ju
    Choi, Michael
    Siddiqi, Tanya
    Barrientos, Jacqueline
    Wierda, William G.
    Isufi, Iris
    Tuscano, Joseph
    Lamanna, Nicole
    Subbiah, Suki
    Koff, Jean L.
    Leslie, Lori A.
    Goldenberg, Alec
    Chung, Gina G.
    Breitmeyer, James B.
    Yazji, Salim
    Wang, Yao
    Wang, Michael
    Jamieson, Catriona
    Kipps, Thomas J.
    BLOOD, 2021, 138
  • [22] Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)
    Lee, Hun Ju
    Choi, Michael Y.
    Siddiqi, Tanya
    Rhodes, Joanna M.
    Wierda, William G.
    Isufi, Iris
    Tuscano, Joseph M.
    Lamanna, Nicole
    Subbiah, Suki
    Koff, Jean L.
    Leslie, Lori
    Goldenberg, Alec
    Chung, Gina G.
    Breitmeyer, James B.
    Yazji, Salim
    Wang, Michael
    Jamieson, Catriona
    Kipps, Thomas J.
    BLOOD, 2022, 140
  • [23] Fixed Duration Combination Therapy with Ibrutinib (ibr) and Venetoclax (ven) Leads to Deep Responses in Relapsed/Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL): Results of a Phase 2 Study
    Siddiqi, Tanya
    Clay, Pamela
    Murray, Kate
    Shekh, Navshina
    Muir, Alexandra
    Rosen, Steven T.
    Coutre, Steven
    BLOOD, 2021, 138 : 3754 - +
  • [24] Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) and Treatment-Naive (TN) Mantle Cell Lymphoma (MCL)
    Lakhotia, Rahul
    Pittaluga, Stefania
    Phelan, James
    Yang, Yandan
    Davies-Hill, Theresa
    Simard, Jillian
    Muppidi, Jagan
    Huang, Da Wei
    Thomas, Craig
    Ceribelli, Michele
    Tosto, Frances
    Pradhan, Amynah
    Juanitez, Anna
    Rimsza, Lisa
    Jacob, Allison
    Simmons, Heidi
    Steinberg, Seth
    Jaffe, Elaine
    Staudt, Louis
    Roschewski, Mark
    Wilson, Wyndham
    Melani, Christopher
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S461 - S461
  • [25] Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) - a Phase II Clinical Trial
    Jain, Preetesh
    Yao, Yixin
    Zhao, Shuangtao
    Liu, Yang
    Hill, Holly
    Che, Yuxuan
    Li, Yijing
    Jordan, Alexa A.
    McIntosh, Joseph
    Lee, Hun Ju
    Steiner, Raphael Eric
    Samaniego, Felipe
    Westin, Jason
    Nastoupil, Loretta J.
    Nair, Ranjit
    Ahmed, Sairah
    Ok, Chi Young
    Kanagal-Shamanna, Rashmi
    Oriabure, Onyeka
    Xu, Guofang
    Chen, Wendy
    Moghrabi, Omar
    McClain, Chloe Marie
    Badillo, Maria
    Thirumurthi, Selvi
    Santos, David
    Iliescu, Cezar
    Yin, C. Cameron
    Li, Shaoying
    Tang, Guilin
    Vega, Francisco
    Neelapu, Sattva S.
    Flowers, Christopher
    Wang, Linghua
    Wang, Michael
    BLOOD, 2020, 136
  • [26] Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study
    Wang, Michael
    Jurczak, Wojciech
    Trneny, Marek
    Belada, David
    Wrobel, Tomasz
    Ghosh, Nilanjan
    Keating, Mary-Margaret
    van Meerten, Tom
    Alvarez, Ruben Fernandez
    von Keudell, Gottfried
    Thieblemont, Catherine
    Peyrade, Frederic
    Andre, Marc
    Hoffmann, Marc
    Glusman, Edith Szafer
    Lin, Jennifer
    Dean, James P.
    Neuenburg, Jutta K.
    Tam, Constantine S.
    BLOOD, 2023, 142
  • [27] Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study
    Wang, Michael
    Jurczak, Wojciech
    Trneny, Marek
    Belada, David
    Wrobel, Tomasz
    Ghosh, Nilanjan
    Keating, Mary-Margaret
    van Meerten, Tom
    Fernandez Alvarez, Ruben
    von Keudell, Gottfried
    Thieblemont, Catherine
    Peyrade, Frederic
    Andre, Marc
    Hoffmann, Marc
    Glusman, Edith Szafer
    Lin, Jennifer
    Dean, James P.
    Neuenburg, Jutta K.
    Tam, Constantine S.
    BLOOD, 2024, 144 : LBA5 - LBA5
  • [28] Initial Report of a Multi-Institution Phase I/Ib Study of Ibrutinib with Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma
    Portell, Craig A.
    Chen, Robert W.
    Wages, Nolan
    Cohen, Jonathon B.
    Weber, Michael J.
    Petroni, Gina
    Kahl, Brad S.
    Williams, Michael E.
    BLOOD, 2016, 128 (22)
  • [29] Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
    Michael Wang
    Radhakrishnan Ramchandren
    Robert Chen
    Lionel Karlin
    Geoffrey Chong
    Wojciech Jurczak
    Ka Lung Wu
    Mark Bishton
    Graham P. Collins
    Paul Eliadis
    Frédéric Peyrade
    Yihua Lee
    Karl Eckert
    Jutta K. Neuenburg
    Constantine S. Tam
    Journal of Hematology & Oncology, 14
  • [30] Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
    Wang, Michael
    Ramchandren, Radhakrishnan
    Chen, Robert
    Karlin, Lionel
    Chong, Geoffrey
    Jurczak, Wojciech
    Wu, Ka Lung
    Bishton, Mark
    Collins, Graham P.
    Eliadis, Paul
    Peyrade, Frederic
    Lee, Yihua
    Eckert, Karl
    Neuenburg, Jutta K.
    Tam, Constantine S.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
12345